SR One Capital Management, LP
About SR One Capital Management, LP’s 13F portfolio
SR One Capital Management, LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , SR One Capital Management, LP reported $1.0B across 15 US-listed positions (). Its largest position is Veradermics, Inc. (MANE) at 28% of the reported book, and its ten biggest holdings make up 95% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NYSE: MANE Veradermics, Inc. | — — | 28% | 2.4M | $295.3M |
| 2 | NASDAQ: ZBIO Zenas BioPharma, Inc | $25.04 −5.22% | 12% | 5.0M | $127.9M |
| 3 | NASDAQ: CRSP CRISPR Therapeutics AG | $38.93 −3.14% | 11% | 2.0M | $111.2M |
| 4 | NASDAQ: AVLN Avalyn Pharma, Inc | — — | 10% | 3.3M | $108.9M |
| 5 | NASDAQ: DSGN Design Therapeutics, Inc. | $9.32 −1.58% | 9.1% | 6.5M | $94.4M |
| 6 | NASDAQ: ODTX Odyssey Therapeutics, Inc. | — — | 6.8% | 3.8M | $71.0M |
| 7 | NASDAQ: ALMS Alumis Inc. | $4.33 −1.48% | 5.3% | 2.0M | $55.2M |
| 8 | NASDAQ: ORIC ORIC Pharmaceuticals, Inc. | $7.70 +0.65% | 4.8% | 4.6M | $50.0M |
| 9 | NASDAQ: MLYS Mineralys Therapeutics Inc. | $14.16 +2.76% | 4.1% | 1.6M | $42.2M |
| 10 | NASDAQ: SPRY ARS Pharmaceuticals, Inc. | $3.36 −8.94% | 3.1% | 4.0M | $32.1M |
| 11 | NASDAQ: MOBI Mobia Medical, Inc | — — | 2.6% | 2.0M | $26.6M |
| 12 | NASDAQ: NKTX Nkarta, Inc. | $1.12 −2.61% | 0.9% | 3.3M | $9.4M |
| 13 | NASDAQ: OCS Oculis Holding AG | $7.44 +0.68% | 0.9% | 641K | $8.9M |
| 14 | NASDAQ: RARE Ultragenyx Pharmaceutical Inc. | $17.22 −2.88% | 0.4% | 138K | $4.6M |
| 15 | NASDAQ: ENGN enGene Holdings Inc. | $1.76 −4.86% | 0.1% | 748K | $1.3M |
Showing the 15 largest positions reported in this 13F.
- Healthcare52%
- NewAVLNAvalyn Pharma, Inc—$108.9M
- NewODTXOdyssey Therapeutics, Inc.—$71.0M
- AddedORICORIC Pharmaceuticals, Inc.+2.2%$50.0M
- NewMOBIMobia Medical, Inc—$26.6M
- SoldORKAOruka Therapeutics, Inc−100%—
- SoldACLXArcellx, Inc.−100%—
Reading SR One Capital Management, LP’s 13F portfolio
SR One Capital Management, LP’s $1.0B 13F book is spread across 15 reported positions and is highly concentrated — its ten largest positions alone are 95% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are MANE, ZBIO, CRSP, AVLN and DSGN, led by Veradermics, Inc. (MANE) at 28% of the portfolio. The heaviest sector exposure is Healthcare (52%).
What SR One Capital Management, LP changed last quarter
Between 2026-03-31 and Q2 2026, SR One Capital Management, LP was a net buyer: it opened 3 new positions and added to 1 more, while trimming 0 and closing 2 outright. Against a 15-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was Avalyn Pharma, Inc (AVLN), and its biggest reduction was Oruka Therapeutics, Inc (ORKA).
What a 13F does and doesn’t reveal
A 13F captures only SR One Capital Management, LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names SR One Capital Management, LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. SR One Capital Management, LP's profile on this page is built directly from those filings.
How current is the 13F data on SR One Capital Management, LP's page?
It reflects SR One Capital Management, LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When SR One Capital Management, LP files its next quarterly report, this page refreshes automatically.
Can I see SR One Capital Management, LP's complete list of holdings?
This page highlights SR One Capital Management, LP's largest positions rather than all 15 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under SR One Capital Management, LP's filings.
Does a 13F show everything SR One Capital Management, LP owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of SR One Capital Management, LP's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why SR One Capital Management, LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

